The #1 Continuous
(CGM) in the US#
FreeStyle Libre 2 system–now available with optional,
real-time glucose alarms*
UNSURPASSED 14-DAY ACCURACY1
- Outstanding accuracy in the low-glucose range1 when it matters the most
- No fingersticks§ required even when glucose is low, falling, or rapidly changing1
OPTIONAL, REAL-TIME GLUCOSE ALARMS*
- Glucose readings every minute5 alert patients the moment their readings are too high or too low
- Excellent, reliable, alarm* performance in the
EASY FOR YOU AND YOUR PATIENTS‡2
- More affordable CGM† at one third the cost of other CGMs**5
- Easy to prescribe with no prior authorizations required††
Libre 2 in action
FreeStyle Libre 2 system
Now offering real-time glucose alarms* for patients with diabetes age 4 and older
Optional, real-time alarms* alert patients the minute they cross the level they set
FreeStyle Libre 2 system meets the highest accuracy standards‡‡
Improved Diabetes Outcomes
Both real-world evidence and clinical trial results highlight the benefits of FreeStyle Libre portfolio‡§§‖‖2,6-10
Easy to prescribe¶¶
Prescriptions can be filled without paperwork hassles or prior authorization at participating pharmacies¶ ¶
Have a sales representative tell you more
A rep can keep you informed about new and existing Abbott products
*Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
†Based on a comparison of list prices of FreeStyle Libre 2 system vs. competitors' CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
‡Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
§Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
‖As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.
¶LibreView is developed, distributed, and supported by Newyu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
#Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
**Based on a comparison of list prices of FreeStyle Libre 2 system vs competitors' CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.
††This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid, or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.
‡‡Based on FDA iCGM special controls.
§§IMPACT Trial: A randomized, controlled 6-month trial to evaluate the effectiveness of FreeStyle Libre glucose monitoring system (n=119) on glycemic control for the self-management of type 1 diabetes (TlD) as compared to self-monitored blood glucose (SMBG; n=120).
‖‖REPLACE Trial: A randomized, control led trial to evaluate the impact of FreeStyle Libre glucose monitoring system (n=149) on HbA1c in people with type 2 diabetes (T2D) taking multiple daily doses of insulin at 6 months compared to self-monitored blood glucose (SMBG; n=75).
¶¶No paperwork hassles or prior authorization needed at participating pharmacies. This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid, or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.
References: 1. FreeStyle Libre 2 system User's Manual. 2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. 3. On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). (https://www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf) 4. The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) subsequently issued guidance on the IFC policies, including discussing that clinical indications for coverage in the therapeutic CGM LCD (Glucose Monitors, L33822) will not be enforced. See “CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised May 21, 2020” (https://www.cgsmedicare.com/jc/pubs/news/2020/05/cope17333.html). 5. Data on file. Abbott Diabetes Care. 6. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388(10057):2254-2263. 7. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium conducted at: 78th Scientific Sessions of the American Diabetes Association; June 22-26, 2018; Orlando, FL. 8. Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83-95. 9. Kroeger J, Fasching P, Hanaire H. Meta-analysis of three, real-world, chart review studies to determine the effectiveness of FreeStyle Libre flash glucose monitoring system on HbA1c in adults with type 2 diabetes. Poster presented at: 79th Scientific Sessions of the American Diabetes Association; June 7-11, 2019; San Francisco, CA. 10. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46.
ADC-12852 v8.0 07/20